LMC005
/ Leman Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
November 25, 2025
Safety and Preliminary Efficacy of a Metabolically Armed Chimeric Antigen Receptor T Cell Therapy Targeting EGFRvIII for Recurrent Glioblastoma
(clinicaltrials.gov)
- P1 | N=36 | Not yet recruiting | Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
New P1 trial • Brain Cancer • Glioblastoma • Oncology • Solid Tumor
1 to 1
Of
1
Go to page
1